Nexavar

Nexavar
Fuse809 (talk) · Public domain · source
Name	Nexavar

Nexavar is a multikinase inhibitor used in the treatment of certain types of cancer, including renal cell carcinoma and hepatocellular carcinoma, as approved by the US Food and Drug Administration and the European Medicines Agency. It is marketed by Bayer and Onyx Pharmaceuticals, and has been shown to improve overall survival in patients with advanced cancer, as demonstrated in clinical trials conducted by National Cancer Institute and American Cancer Society. Nexavar has also been investigated in combination with other anticancer agents, such as bevacizumab and temsirolimus, in studies sponsored by National Institutes of Health and Cancer Research UK. The development of Nexavar involved collaborations between Bayer, Onyx Pharmaceuticals, and University of California, San Francisco, with funding from National Cancer Institute and American Association for Cancer Research.

● Introduction

Nexavar, also known as sorafenib, is a small molecule inhibitor that targets multiple kinases, including RAF kinase, VEGFR, and PDGFR, which are involved in tumor growth and angiogenesis, as described by Robert Kerbel and Judah Folkman. The drug has been evaluated in various clinical trials, including the SHARP trial and the TARGET trial, which were conducted by Bayer and Onyx Pharmaceuticals in collaboration with Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. Nexavar has been compared to other tyrosine kinase inhibitors, such as sunitinib and imatinib, in terms of its efficacy and safety profile, as reported by Journal of Clinical Oncology and New England Journal of Medicine. The use of Nexavar has been supported by American Society of Clinical Oncology and European Society for Medical Oncology, and has been included in treatment guidelines developed by National Comprehensive Cancer Network and European Association for the Study of the Liver.

● Medical_Uses

Nexavar is indicated for the treatment of renal cell carcinoma, hepatocellular carcinoma, and radioactive iodine-resistant advanced thyroid cancer, as approved by US Food and Drug Administration and European Medicines Agency. It has also been investigated in the treatment of other types of cancer, including breast cancer, lung cancer, and colorectal cancer, in clinical trials conducted by National Cancer Institute and American Cancer Society. The use of Nexavar in combination with other anticancer agents, such as chemotherapy and hormone therapy, has been evaluated in studies sponsored by National Institutes of Health and Cancer Research UK. Nexavar has been compared to other targeted therapies, such as bevacizumab and trastuzumab, in terms of its efficacy and safety profile, as reported by Journal of Clinical Oncology and New England Journal of Medicine. The development of Nexavar involved collaborations between Bayer, Onyx Pharmaceuticals, and University of California, San Francisco, with funding from National Cancer Institute and American Association for Cancer Research.

● Mechanism_of_Action

Nexavar works by inhibiting multiple kinases, including RAF kinase, VEGFR, and PDGFR, which are involved in tumor growth and angiogenesis, as described by Robert Kerbel and Judah Folkman. The inhibition of these kinases leads to a decrease in tumor blood flow and a reduction in tumor growth, as demonstrated in preclinical studies conducted by Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. Nexavar has also been shown to induce apoptosis in cancer cells, as reported by Journal of Clinical Oncology and New England Journal of Medicine. The mechanism of action of Nexavar is similar to that of other tyrosine kinase inhibitors, such as sunitinib and imatinib, which are used in the treatment of various types of cancer, including renal cell carcinoma and gastrointestinal stromal tumor. The use of Nexavar has been supported by American Society of Clinical Oncology and European Society for Medical Oncology, and has been included in treatment guidelines developed by National Comprehensive Cancer Network and European Association for the Study of the Liver.

● Side_Effects

The most common side effects of Nexavar include fatigue, diarrhea, and rash, as reported by Journal of Clinical Oncology and New England Journal of Medicine. Other side effects may include hypertension, cardiac ischemia, and bleeding, as described by Robert Kerbel and Judah Folkman. The risk of side effects may be increased when Nexavar is used in combination with other anticancer agents, such as chemotherapy and hormone therapy, as demonstrated in clinical trials conducted by National Cancer Institute and American Cancer Society. The management of side effects is an important aspect of the treatment of cancer with Nexavar, and may involve the use of supportive care measures, such as antiemetics and pain management, as recommended by American Society of Clinical Oncology and European Society for Medical Oncology. The development of Nexavar involved collaborations between Bayer, Onyx Pharmaceuticals, and University of California, San Francisco, with funding from National Cancer Institute and American Association for Cancer Research.

● History

Nexavar was first approved by the US Food and Drug Administration in 2005 for the treatment of renal cell carcinoma, and was later approved for the treatment of hepatocellular carcinoma in 2007, as reported by Journal of Clinical Oncology and New England Journal of Medicine. The development of Nexavar involved collaborations between Bayer, Onyx Pharmaceuticals, and University of California, San Francisco, with funding from National Cancer Institute and American Association for Cancer Research. Nexavar has been evaluated in various clinical trials, including the SHARP trial and the TARGET trial, which were conducted by Bayer and Onyx Pharmaceuticals in collaboration with Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. The use of Nexavar has been supported by American Society of Clinical Oncology and European Society for Medical Oncology, and has been included in treatment guidelines developed by National Comprehensive Cancer Network and European Association for the Study of the Liver.

● Pharmacology

Nexavar is a small molecule inhibitor that is administered orally, as described by Robert Kerbel and Judah Folkman. The pharmacokinetics of Nexavar have been evaluated in clinical trials, and the drug has been shown to have a half-life of approximately 25-48 hours, as reported by Journal of Clinical Oncology and New England Journal of Medicine. The metabolism of Nexavar involves the cytochrome P450 enzyme system, and the drug is primarily eliminated through the feces, as demonstrated in preclinical studies conducted by Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. The use of Nexavar has been supported by American Society of Clinical Oncology and European Society for Medical Oncology, and has been included in treatment guidelines developed by National Comprehensive Cancer Network and European Association for the Study of the Liver. The development of Nexavar involved collaborations between Bayer, Onyx Pharmaceuticals, and University of California, San Francisco, with funding from National Cancer Institute and American Association for Cancer Research. Category:Anticancer drugs